Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

BACKGROUND: There is strong evidence demonstrating that activation of epidermal growth factor receptors (EGFRs) leads to tumor growth, progression, invasion and metastasis. Erlotinib and gefitinib, two EGFR-targeted agents, have been shown to be relevant drugs for lung cancer treatment. Recent studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz, Roque, Nguewa, Paul A, Parrondo, Ricardo, Perez-Stable, Carlos, Manrique, Irene, Redrado, Miriam, Catena, Raul, Collantes, Maria, Peñuelas, Ivan, Díaz-González, Juan Antonio, Calvo, Alfonso
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883966/
https://www.ncbi.nlm.nih.gov/pubmed/20459769
http://dx.doi.org/10.1186/1471-2407-10-188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883966/
https://www.ncbi.nlm.nih.gov/pubmed/20459769
http://dx.doi.org/10.1186/1471-2407-10-188

Ejemplares similares